Visgenx Company
%20.jpg)
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
Founded Date:
2018-01-01
Last Funding Type:
Seed
Headquarters:
San Diego, California, United States
Investors Number:
2
Technology:
Regenerative Medicine
Employee Number:
1-10
Industry:
Biotechnology, Medical, Therapeutics
Total Funding:
$2.3M